(Q42745153)

English

Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy

scientific article published on January 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

T Aihara

1

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

K Suemasu

2

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

H Takei

3

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

Y Hozumi

4

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

M Takehara

5

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

T Saito

6

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

S Ohsumi

7

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

N Masuda

8

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

Y Ohashi

9

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

publication date

1 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

79

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

5-6

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

376-381

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

Emerging role of aromatase inhibitors in the adjuvant setting

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients: is there a racial difference?

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Exemestane: a review of its use in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX)

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1159%2F000323489

21 January 2018

Identifiers

10.1159/000323489

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

release_zlinsicxrze4hcak6ibaq632bi

1 reference

https://api.fatcat.wiki/v0/release/zlinsicxrze4hcak6ibaq632bi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42745153&oldid=1968652953"